Sangamo Therapeutics (SGMO) Stock Price, Quote & News

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 970 6000

Website: www.sangamo.com

Address:

501 Canal Blvd, Richmond, United States

JimiJoJeeter Oct. 27 at 3:13 PM

$SGMO Hmmmmm.... the extension was probably requested!

0 · Reply

biotech Oct. 27 at 3:01 PM

$SGMO shorts covering 1.7M shares

0 · Reply

JimiJoJeeter Oct. 27 at 2:53 PM

$SGMO Looks like the jury is in early. I'm seeing a dair amount of red. Looks like the market is still oblivious to the differences between crspr and zfn editing, regulation, and therapy. Great time for a statrment about it ftom MacFuckFace. Oh wait, he's too busy polishing his fangs, preparing to suck more money out of shareholders!

1 · Reply

SilentSniper Oct. 27 at 2:20 PM

$SGMO Sangamo and its safe Zinc Finger tech stand to benefit with the downfall of CRSPR

3 · Reply

Badrabitt Oct. 27 at 2:00 PM

$SGMO Looks like were going back down first floor

0 · Reply

Prittykitty Oct. 27 at 1:25 PM

$SGMO everyone already knew crispr products are wild cards. Lets get this buyout done already.

0 · Reply

JimiJoJeeter Oct. 27 at 1:24 PM

$SGMO Will NTLA drag all biotech down with it? Anyone care to guess?

2 · Reply

Top_Dog_Pro_Trader Oct. 27 at 12:42 PM

$SGMO looks like CRSP’s gene editing has some major issues. SGMO’s perhaps largest competitor maybe toast…IMO!

1 · Reply

Moveme1mm Oct. 27 at 12:40 PM

$SGMO

0 · Reply

GothamGirl Oct. 27 at 12:23 PM

$SGMO NTLA down 46% premarket on liver issues. Will this be good or bad news for SGMO?

1 · Reply

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Aug 8, 2025, 2:53 PM EDT - 2 months ago

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 31, 2025, 4:05 PM EDT - 3 months ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jun 24, 2025, 8:05 AM EDT - 4 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

May 12, 2025, 9:06 PM EDT - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:26 PM EDT - 5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:23 PM EDT - 5 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 4:00 PM EDT - 5 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 6, 2025, 4:35 PM EDT - 6 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 8:30 AM EDT - 6 months ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Apr 28, 2025, 4:31 PM EDT - 6 months ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 4, 2025, 2:57 PM EDT - 7 months ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 3, 2025, 4:01 PM EDT - 7 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 17, 2025, 6:29 PM EDT - 7 months ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 7 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 8 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Feb 6, 2025, 8:05 AM EST - 9 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 15, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 14, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 10 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 10, 2025, 10:00 AM EST - 10 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 8, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 6, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 5, 2025, 10:00 AM EST - 10 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 2, 2025, 6:00 PM EST - 10 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 4:00 PM EST - 10 months ago

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Jan 2, 2025, 3:05 PM EST - 10 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Jan 2, 2025, 10:15 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Dec 31, 2024, 12:01 PM EST - 10 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 11:22 AM EST - 10 months ago

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

PFE

JimiJoJeeter Oct. 27 at 3:13 PM

$SGMO Hmmmmm.... the extension was probably requested!

0 · Reply

biotech Oct. 27 at 3:01 PM

$SGMO shorts covering 1.7M shares

0 · Reply

JimiJoJeeter Oct. 27 at 2:53 PM

1 · Reply

SilentSniper Oct. 27 at 2:20 PM

$SGMO Sangamo and its safe Zinc Finger tech stand to benefit with the downfall of CRSPR

3 · Reply

Badrabitt Oct. 27 at 2:00 PM

$SGMO Looks like were going back down first floor

0 · Reply

Prittykitty Oct. 27 at 1:25 PM

$SGMO everyone already knew crispr products are wild cards. Lets get this buyout done already.

0 · Reply

JimiJoJeeter Oct. 27 at 1:24 PM

$SGMO Will NTLA drag all biotech down with it? Anyone care to guess?

2 · Reply

Top_Dog_Pro_Trader Oct. 27 at 12:42 PM

$SGMO looks like CRSP’s gene editing has some major issues. SGMO’s perhaps largest competitor maybe toast…IMO!

1 · Reply

Moveme1mm Oct. 27 at 12:40 PM

$SGMO

0 · Reply

GothamGirl Oct. 27 at 12:23 PM

$SGMO NTLA down 46% premarket on liver issues. Will this be good or bad news for SGMO?

1 · Reply

biotech Oct. 27 at 11:47 AM

$SGMO NON CRISPR GENE EDITING re $NTLA news crashing $CRSP and crispr dirt stocks Sangamo only perfect safe gene editor not using this crispr killer stuff

0 · Reply

MAKO1992 Oct. 27 at 11:07 AM

$SGMO Takeda and Astellas earnings reports this Thursday... maybe we are waiting for this

2 · Reply

Ali100_A Oct. 27 at 11:01 AM

$SGMO Sandy, when will you pull your fingers out of your backside and do something like this: https://www.fiercebiotech.com/biotech/novartis-goes-big-neuroscience-12b-deal-late-stage-dystrophy-biotech-avidity

0 · Reply

TwoThirdsProbablyDown Oct. 27 at 10:38 AM

$SGMO silence is good because it means negotiations might be in the works. Press releases about nothing are what you need to be afraid of.

0 · Reply

TwoThirdsProbablyDown Oct. 27 at 10:37 AM

$SGMO is this the week?

0 · Reply

BuyThisOne Oct. 27 at 10:16 AM

$SGMO Am I going to lose 80k here or get richer? It is hard to have any feelings here right now. I have hope but damn the silence is deafening.

0 · Reply

Stueytothemoon Oct. 26 at 7:32 PM

$SGMO there is not only one form 4 that has been filed. There are multiple on the investors page!! Take a look and share your opinions of what that means?

4 · Reply

Ride2Abide Oct. 26 at 7:24 PM

$SGMO 12 Billion rare disease Co. buyout is nice to see: Swiss pharmaceutical giant Novartis $NVS announced Sunday it had agreed to buy Avidity Biosciences, with the San Diego-based biopharmaceutical company being valued at $12 billion.

0 · Reply

Ihuarraqax123 Oct. 26 at 2:47 PM

$SGMO tomorrow delisting, rubish stock. Over 10k usd lost.

3 · Reply

Sloppyb Oct. 26 at 2:43 PM

$SGMO @Futurision how are you feeling about our odds this week?

2 · Reply

809trader Oct. 25 at 10:45 PM

$SGMO I’m gonna leave this here.

0 · Reply

Swamp_Yankee Oct. 25 at 9:25 PM

$SGMO I'm gonna buy all of razzledazzles shares when he folds this week. And he will fold.

1 · Reply

Market Cap	191.07M
Revenue (ttm)	57.80M
Net Income (ttm)	-97.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-169.45%
Debt to Equity Ratio	0.00

Volume	4,322,100
Avg Vol	4,992,576
Day's Range	N/A - N/A
Shares Out	301.71M
Stochastic %K	20%
Beta	1.22
Analysts	Strong Sell
Price Target	$4.10